<DOC>
	<DOCNO>NCT02251171</DOCNO>
	<brief_summary>Study determine effect steady-state Tipranavir ( TPV ) / Ritonavir ( RTV ) ( 500mg/200mg bid ) single-dose pharmacokinetics Rifabutin ( RFB ) determine effect single-dose RFB steady-state pharmacokinetics TPV 500mg ( co-administered RTV 200mg )</brief_summary>
	<brief_title>Effects Steady-state TPV/RTV Single-dose Pharmacokinetics Rifabutin Effects Single-dose Rifabutin Steady-state Pharmacokinetics TPV Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>1 . Male female subject 18 60 year age inclusive 2 . A Body Mass Index ( BMI ) 18 29 kg/m2 3 . Signed informed consent prior trial participation 4 . Ability swallow multiple large capsule without difficulty 5 . Acceptable laboratory value indicate adequate baseline organ function require time screen . Laboratory value consider acceptable severity less equal Grade 1 , base AIDS Clinical Trials Group ( ACTG ) Grading Scale . All abnormal laboratory value great Grade 1 subject approval trial clinical monitor 6 . Acceptable medical history , physical examination , 12lead ECG require prior enter treatment phase study . The requirement chest Xray leave investigator 's discretion 7 . Willingness abstain follow start 14 day prior administration study drug end study : Grapefruit grapefruit juice Red wine Seville oranges St. John 's Wort Milk Thistle 8 . Willingness abstain alcohol start 2 day prior administration study drug end study 9 . Willingness abstain follow within 72 hour pharmacokinetic ( PK ) sampling : Garlic supplement Methylxanthine contain drink ( coffee , tea , cola , energy drink , chocolate , etc . ) 10 . Willingness abstain counter herbal medication duration study 11 . Have nonsmoker 3 month 12 . Willingness abstain vigorous physical exercise intensive PK study Days 1 , 14 , 15 13 . Reasonable probability completion study As guideline , subject abnormal laboratory value screen , take prescription medication exclude : 1 . Female subject reproductive potential : Have positive serum Î²human chorionic gonadotropin Visit 1 , study Day 0 study Day 1 Have use barrier contraceptive method least 3 month prior Visit 3 ( study Day 1 ) Are willing use reliable method barrier contraception ( diaphragm spermicidal cream/jelly condoms spermicidal foam ) , trial 60 day completion/termination Are breastfeed 2 . Participation another trial investigational medicine within 60 day prior study Day 0 ( Visit 2 ) 3 . Use medication list Protocol within 30 day prior study Day 0 ( Visit 2 ) 4 . Use pharmacological contraceptive ( include oral , patch injectable contraceptive ) within 1 month prior study Day 0 duration study . Use DepoProvera exclude six month prior study Day 0 5 . Use hormone replacement therapy within 1 month prior study Day 0 duration study 6 . Administration antibiotic within 10 day prior study Day 0 ( Visit 2 ) trial 7 . History acute illness within sixty ( 60 ) day study Day 0 . Subjects exclude acute illness great sixty day prior study Day 0 , opinion investigator , subject qualify healthy volunteer 8 . History thrombotic disease 9 . History migraine headache 10 . Have serological evidence hepatitis B C virus 11 . Have serological evidence exposure HIV 12 . Recent history alcohol substance abuse ( within 1 year screening ) 13 . Blood plasma donation within 30 day prior study Day 0 ( Visit 2 ) trial 14 . Subjects seat systolic blood pressure either &lt; 100 mm Hg &gt; 150 mm Hg ; rest heart rate either &lt; 50 beats/min &gt; 90 beats/min . For subject rest heart rate 50 , 90 , investigator may discuss exclusion clinical monitor casebycase basis 15 . Subjects history illness allergy , opinion investigator , might confound result study pose additional risk administer TPV , RTV RFB subject 16 . Subjects take ( within 7 day prior study Day 0 ) take overthecounter prescription drug , opinion investigator consultation clinical monitor , might interfere either absorption , distribution metabolism test substances 17 . Known hypersensitivity TPV , RTV , RFB , sulphonamide class drug 18 . Inability adhere protocol 19 . Cautions warning RTV RFB package insert , judgment investigator , exclude subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>